MUC16 and ovarian cancer: Indeed, the AUC testing for significant differences between CA125 and the three-biomarker panel shows no difference versus stages III+IV and clear but modest significant differences versus the total (P = 0.012) and stages I+II ovarian cancer (P = 0.014).